Speaker illustration

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

Cardiovascular outcomes & atherosclerosis: How do GLP-1 receptor antagonist provide benefits?

Event: ESC Congress 2020

Topic: Diabetes and the Heart

Session: Expanding focus for cardiologists: The diabetic patient and cardiovascular outcomes

Thumbnail

Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.

Event: ESC Congress 2018

Topic: Secondary Prevention

Session: LDL-c: done deal, next epigenetics? (EBAC Accredited)

Thumbnail

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Event: ESC Congress 2017

Topic: Diabetes, dysglycaemia and metabolic syndrome

Session: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Thumbnail

Cardiovascular effects of GLP-1 receptor agonists.

Event: ESC Congress 2017

Topic: Diabetes, dysglycaemia and metabolic syndrome

Session: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Thumbnail

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation.

Event: ESC Congress 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: A novel approach for high CV risk patients with diabetes: the potential of epigenetics

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb